Effective August 2, 2022, mdxhealth has acquired the Oncotype DX GPS (Genomic Prostate Score) test from Exact Sciences. To help ensure a smooth transition for patients, continue to place orders for this test through the existing Exact Sciences portal until further notice. Additionally, Genomic Health Inc, part of Exact Sciences, will continue to perform the Oncotype DX GPS test during the transition. Further communications explaining transition plans will be provided in the coming months. For more details, please review the following press release. Questions? Email: gps@mdxhealth.com

For men diagnosed with low-, intermediate-, and high-risk localized prostate cancer, Exact Sciences offers the Oncotype DX Genomic Prostate Score® (GPS) test, which measures the expression of certain genes in prostate cancer cells to help guide treatment decisions at the time of a patient’s diagnosis.1

The results are reported as a Genomic Prostate Score® result, which can help patients and their physicians make decisions about an appropriate management plan.2

With two tailored test reports, the GPS test provides useful information for when active surveillance may be an appropriate decision for low-risk patients, as well as risk estimates to help inform treatment decisions and treatment intensity for higher risk patients.3


1Klein et al. Eur Urol. 2014.

2Badani et al. Urol Pract. 2015.

3Data on file